Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

National Institute for Health and Care Excellence

Charity launches petition calling for NICE to rethink MS drug decision

The MS Society has launched a petition calling for the National Institute for Health and Care Excellence (NICE), NHS England and drug manufacturer, Roche, to rethink NICE’s decision to reject the first treatment to be licensed for the treatment of primary progressive multiple sclerosis (PPMS).

NICE announced on 10 September 2018 that it would not be making ocrelizumab for PPMS available on the NHS in England and Wales, on the grounds that the drug was too expensive.

According to the charity, there are currently no disease-modifying therapies (DMTs) for this type of multiple sclerosis (MS); therefore, it said it was imploring the three organisations to agree a deal to enable ocrelizumab to be made available on the NHS to anyone who could benefit.

“This is a deeply disappointing decision, denying many desperate people access to a treatment which may slow down their disability progression,” said Genevieve Edwards, director of external affairs at the MS Society.

“MS can be painful and often exhausting, and for many people living with the primary progressive form — which currently has no treatment on the NHS — ocrelizumab offered them a shot at a better future.

“Right now our utmost priority is ensuring everyone who could benefit from this treatment is given that opportunity.”

MS affects more than 100,000 people in the UK, and one in eight people with MS are diagnosed with PPMS, meaning that approximately 625 people each year could benefit from ocrelizumab.

The petition can be found on the MS Society website.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20205434

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • Applications of LC-MS in Toxicology

    Applications of LC-MS in Toxicology

    Practical, hands-on information on the application of LC-MS in the field of toxicology.

    £140.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.